secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aprea Therapeutics, Inc. (APRE)
CIK:        0001781983
Form:       8-K
Filed at:   2023-08-24T23:59:59+00:00
Accession:  0001558370-23-015237
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02, 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Aprea Therapeutics Board Chair Christian Schade resigns; Richard Peters named Chair, Jean-Pierre Bizzari appointed
--------------------------------------------------------------------------------

- Christian S. Schade resigned as director and Board Chair on Aug 23, 2023; no disagreement with company.
- Richard Peters, M.D., Ph.D. appointed Board Chair effective immediately after Schade's resignation.
- Dr. Jean-Pierre Bizzari appointed as Class III director through 2025 annual meeting; previously at Celgene and Sanofi.
- Annual meeting: Class I directors Duey, Peters, Seizinger elected (~1.55M for); auditor EisnerAmper LLP ratified (2.05M for).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1781983/000155837023015237/0001558370-23-015237-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1781983/000155837023015237/apre-20230823x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-015237

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer